Complement activation by IgM autoantibodies linked to immune‐mediated neuropathies depends on C2
European Journal of Neurology · 2025
DOI: 10.1111/ene.16541 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Kevin Budding und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Immunoglobulin M, Autoantibodies, Complement Activation, Complement C2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose Complement factor C2 is a potential therapeutic target in immune‐mediated neuropathies. However, literature suggests that classical complement pathway activation may proceed to C3 in the absence of C2, a so‐called “C2 bypass.” Here, we evaluated a C2 bypass mechanism during complement activation by pathogenic human IgM from patients with immune‐mediated neuropathies.
Methods
IgM autoantibodies from 51 patients with multifocal motor neuropathy (MMN) or anti‐myelin‐associated glycoprotein (MAG) neuropathy (AMN) were used to activate complement in ex vivo disease models. C2 bypass was evaluated using C2‐depleted (C2D) serum and a therapeutic anti‐C2 antibody.
Results
In two different disease models of MMN, IgM anti‐GM1 and IgM anti‐GM2 autoantibodies from MMN patients were bound to induced pluripotent stem cell‐derived motor neurons and Schwann cells, respectively, and fixed C3 upon incubation with fresh serum. C3 fixation was inhibited by anti‐C2 and did not occur with C2D serum. Similarly, in an AMN model, IgM anti‐MAG antibodies were incubated with fresh serum and fixed C3, which in all cases was abrogated in the absence of C2 or in the presence of anti‐C2.
Conclusions
In ex vivo disease models of MMN and AMN, complement activation by IgM autoantibodies from 51 patients was in all cases dependent on C2 and was inhibited by an antihuman C2 antibody. No evidence of a C2 bypass mechanism was found.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- Department of Neurology and Neurosurgery, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.
- Department of Translational Neuroscience, University Medical Center Utrecht Brain Center, Utrecht University, Utrecht, the Netherlands.
- Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
- argenx, Ghent, Belgium.
ORCID-Profile: Kevin Budding
Zitieren
APA
Budding, K., Dijkxhoorn, K., de Zeeuw, E., Bloemenkamp, L. M., van der Pol, W. L., Notermans, N. C., Minnema, M. C., Leusen, J. H. W., Hack, C. E., & Van de Walle, I. (2025). Complement activation by IgM autoantibodies linked to immune‐mediated neuropathies depends on C2. European Journal of Neurology. https://doi.org/10.1111/ene.16541
Vancouver
Budding K, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, van der Pol WL, Notermans NC, et al. Complement activation by IgM autoantibodies linked to immune‐mediated neuropathies depends on C2. European Journal of Neurology. 2025. doi:10.1111/ene.16541
BibTeX
@article{Budding2025,
author = {Budding, Kevin and Dijkxhoorn, Kim and de Zeeuw, Elisabeth and Bloemenkamp, Lauri M and van der Pol, W Ludo and Notermans, Nicolette C and Minnema, Monique C and Leusen, Jeanette H W and Hack, C Erik and Van de Walle, Inge},
title = {Complement activation by IgM autoantibodies linked to immune‐mediated neuropathies depends on C2},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.16541}
}
EUVIMED